Srikala Sridhar

Srikala Sridhar is a GU medical oncologist and clinical investigator specializing in urothelial malignancies with a focus on immunotherapy and antibody-drug conjugates. She has been involved in major clinical trials including EV-302 establishing enfortumab vedotin plus pembrolizumab as first-line standard of care in advanced urothelial cancer. She leads the GU medical oncology program at Princess Margaret and has contributed to clinical research spanning bladder cancer, upper tract, and penile cancers. She is also engaged in cancer survivorship research addressing long-term treatment effects.